AngioDynamics earnings beat by $0.02, revenue topped estimates

AngioDynamics reported Q3 EPS of -$0.07, beating the -$0.09 consensus by $0.02, and revenue of $78.42M versus $76.71M estimates. FY2026 guidance: EPS -$0.30 to -$0.23 (consensus -$0.29) and revenue $313.5M-$315.5M (consensus $312.9M), both slightly above street expectations. Shares closed at $11.94; down 5.84% over 3 months but up 21.59% over 12 months, and the company saw 0 positive vs 3 negative EPS revisions in the past 90 days; InvestingPro flags Financial Health as "good performance."

Analysis

AngioDynamics sits at the intersection of recurring consumables and elective-procedure cyclicality — that combination amplifies short-term sensitivity to macro shocks but preserves medium-term cash flows if procedure volumes normalize. Management levers (SG&A pruning, SKU rationalization, pricing vs. mix) can restore margin within 2–6 quarters; conversely, sustained hospital revenue pressure would show up first in consumables volume and then in order cadence from GPOs.

The market appears to be discounting execution risk more than structural demand risk: small-device players typically re-rate on either accelerating share gains in core niches (vascular access, oncology ablation) or on margin improvement from fixed-cost deleverage. Key non-obvious inputs are hospital capital cycles and outpatient-conversion rates — faster outpatient shift favors lower-cost disposable portfolios and should be a multi-year tailwind for firms with a consumables-heavy mix.

Near-term catalysts that will force re-pricing are upcoming quarterly cadence, any discrete reimbursement or GPO contract news, and clinical/recall headlines; geopolitical-driven energy or macro shocks can compress elective volumes within weeks and are the fastest path to negative revisions. Balance-sheet optionality (tuck-in M&A or buybacks) is an underappreciated upside if margins stabilize, while prolonged multiple negative EPS revisions remain the primary downside driver over 3–12 months.

Key Decisions for Investors

• Directional play (reward 2.5x, risk 1x): Establish a 4–6% portfolio position long ANGO with a 6–12 month horizon, size to a stress loss of 25% of position value, and sleeve a protective collar (buy 12-month 20% OTM puts + sell 12-month 10% OTM calls) to cap downside while keeping meaningful upside to a re-rating.
• Event-driven pair (market-neutral, reward 1.5x, risk 1x): Long ANGO vs short a diversified large-cap med-tech (e.g., BSX or MDT) for 3–6 months to isolate small-cap execution risk; size 1:1 notional and tighten if hospital volume datapoints diverge, pocketing spread if ANGO stabilizes and the large-cap outperforms on safe-haven flow.
• Volatility hedge (asymmetric protection): Buy near-term (30–90 day) puts ~15–20% OTM ahead of next earnings and macro event windows sized to limit portfolio drawdown from a sector-wide elective slowdown; if no downside materializes, roll into longer-dated protection at lower cost.
• Contrarian catalyst trade (high optionality): Buy 12–18 month call spreads on ANGO (buy 20% OTM, sell 40% OTM) sized small (1–2% portfolio) to capture upside from margin recovery or M&A optionality — limited premium outlay with levered upside if management executes on cost and cross-sell.
• Trigger-based action: Set alerts for (A) a sequential improvement in consumables volume growth or gross margin over two consecutive quarters — add to longs; (B) another downward EPS revision or GPO-share loss — trim longs and rotate into larger-cap, lower-beta device names.